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“Et tu quoque, mi fili!”
(And thou too, my son)
-Julius Caesar
The history of p53 is a chaotic voyage
from the world of oncogenes to the world
of tumor suppressor genes, while retain-
ing a certain degree of individuality.
Apart from artifactual problems related to
involuntary cloning of mutant p53, this
ambiguity is also due to our propensity to
overcategorize in order to satis-
fy our Cartesian and oversim-
plistic view of science. Two
articles published in this issue of
Cancer Cell suggest that, once
again, we need to revise our
ideas concerning, not wild-type
p53, which for the moment
retains its tumor suppressor
gene status, but mutant p53,
which must now be considered
to be oncogenes actively partici-
pating in the tumor phenotype
(Bergamaschi et al., 2003; Irwin
et al., 2003).
The idea that some p53
mutations can actively partici-
pate in cellular transformation
was already postulated in 1990,
and several arguments are in
favor of such a model (Eliyahu et
al., 1990; Lane and Benchimol,
1990). First of all, the mode of
“inactivation” of wild-type p53:
unlike most other tumor sup-
pressor genes that are inactivat-
ed by frameshift or nonsense
mutations leading to disappear-
ance or aberrant synthesis of
the gene product, almost 90% of
p53 gene mutations are mis-
sense mutations leading to the
synthesis of a stable protein,
lacking its specific DNA binding
function and accumulating in the
nucleus of tumor cells (Soussi
and Béroud, 2001). This particu-
lar selection for accumulation of
p53 mutations in tumor cells can
have two consequences: (1) a
dominant negative role by het-
erooligomerization with wild-
type p53 expressed by the second allele,
or (2) a specific gain of function of mutant
p53. Many studies have tried to distin-
guish between these two hypotheses,
with no clear-cut conclusions.This task is
further complicated by the fact that not
all p53 mutations appear to be equiva-
lent and present a marked heterogeneity
of structure or loss of function.
Transfection of various p53 mutations
into cells devoid of endogenous p53
leads to an increase in their carcino-
genicity, which varies according to the
type of mutation (Dittmer et al., 1993;
Halevy et al., 1990). This research into
the oncogenic potential of certain p53
mutations is not purely theoretical, but
has obvious clinical implications, as it
could explain the marked disparity of the
results of studies trying to demonstrate a
relationship between the presence of a
p53 gene mutation and various clinical
parameters, such as survival or
response to treatment. In breast cancer
patients, the response to adri-
amycin is very strongly correlat-
ed with the presence of a
mutation specifically localized in
the loop domains L2 or L3 of the
p53 protein (Aas et al., 1996). In
vitro, the expression of p53
mutations in position 175
(R175H) specifically induces
resistance of cells to etoposides
compared to other p53 muta-
tions (Blandino et al., 1999).
The studies described by
Crook and Kaelin in this issue of
Cancer Cell show that this activi-
ty of resistance to anticancer
agents involves inactivation of
the apoptotic function of p73 pro-
tein by mutant p53 (Bergamaschi
et al., 2003; Irwin et al., 2003).
The two homologous genes of
p53, p63 and p73, discovered 6
years ago, express many iso-
forms due to alternating use of
transcription promoters and
alternative splicing. Long iso-
forms (TA-p73 or TA-p63) are
able to transactivate the same
target genes as p53 and induce
apoptosis, while short forms
(∆N-p63 or ∆Np73) have an
opposite activity via dominant
negative mechanisms (Melino et
al., 2002). p63 and p73 are able
to cooperate with p53 to induce
apoptosis, suggesting the exis-
tence of a complex network of
interactions between the prod-
ucts of these three genes (Flores
et al., 2002). The mechanism by
which p53 and its two siblings
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p53 mutations and resistance to chemotherapy:
A stab in the back for p73
p73 is essential for apoptosis induced by many cytotoxic agents, but this function can be blocked by a particular category
of p53 mutations that have consequently acquired a gain of function.
Figure 1. Cooperation of p53, p63, and p73 in response to DNA
damage
In a normal cell, the signaling pathways leading to DNA dam-
age apoptosis is controlled by a cooperation of p53, p63 and
p73. How these 3 proteins cooperate is still unknown. In tumor
cells, alteration of p53 can lead to at least 3 types of mutant
p53: (A) inactive mutants with no dominant negative activity
on p53; (B) inactive mutants with a dominant negative activity
by interaction with wild-type p53; and mutants with a gain of
function via inactivation of p73-dependent apoptosis and per-
haps p63 as well (C).
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cooperate for apoptosis after DNA dam-
age is largely unknown, but two models
have been provided (Urist and Prives,
2002). In the “dynamic exchange” model,
p53 and p63 and/or p73 reside in a large
transcriptional complex that sequesters
the 3 proteins close to the promoter ele-
ment. At any time, one of the 3 proteins
may bind to DNA to activate transcription
(Figure 1). It is possible that this large
complex is stabilized by p63, p73, or
both.The “dual site stabilization” model is
based on the observation that several
genes contain more than one p53
response element. Engagement of these
two response elements by p53 and p73
and/or p63 could be required for the most
efficient transcription.
Irwin et al. show that many genotoxic
agents can induce accumulation of p73
protein in cell lines of tumor cells (Irwin et
al., 2003). Inactivation of p73 by a domi-
nant negative mutation or si-RNA leads
to resistance of cells to apoptosis
induced by genotoxic agents. Similarly,
p73−/− murine embryonic fibroblasts
immortalized by SV40 antigen T and Ha-
ras are more resistant to apoptosis
induced by these genotoxic agents than
the same cells expressing wild-type p73.
This chemoresistance induced by inacti-
vation of p73 is independent of the p53
gene status. Similarly, Crook’s team
shows that adriamycin, cisplatin, taxol,
and etoposide induce accumulation of
p73 protein and induction of AIP gene
transcription (apoptosis induced protein),
thereby confirming that p73 is an
important component in the cell response
to cytotoxic agents (Bergamaschi et al.,
2003).
As the p73 gene is only rarely geneti-
cally or epigenetically altered in human
tumors, is it possible to consider another
indirect mechanism leading to p73 inacti-
vation? This is a fundamental question,
as p73 inactivation could explain certain
mechanisms of resistance to chemother-
apy. The answer to this question can be
found in studies of the protein interac-
tions between the various members of
the p53 family. Although it has now been
fairly clearly established that wild-type
p53 cannot form stable heteroligomers
with p73 or p63, this is not the case for
mutant p53. A strong interaction involving
the DNA binding domain of the two part-
ners has been characterized between
certain p53 mutations and p73 or p63
(DiComo et al., 1999; Marin et al., 2000;
Strano et al., 2002). This interaction also
leads to inactivation of the transactiva-
tional functions of p73 and p63. Various
types of p53 mutations can interact with
p73, depending on the author and exper-
imental conditions, but recent studies
show that a change of conformation of
the central domain of mutant p53 is the
essential component in this interaction
with p73 (Bensaad et al., 2003). On the
other hand, in a joint study, Kaelin and
Crook showed that p53 polymorphism in
codon 72 (Arg or Pro) had an important
influence on this interaction, as it is only
detected in mutant p53 with Arg polymor-
phism (Marin et al., 2000).
In this issue of Cancer Cell,
Bergamaschi et al. used isogenic cell
lines expressing a great diversity of p53
mutations either in the Arg form or the
Pro form and show that only those
mutants expressing the Arg form are
resistant to cytotoxic agents
(Bergamaschi et al., 2003). Furthermore,
analysis of a homogeneous population
of patients with head and neck cancer
presenting identical p53 mutations to
those studied in vitro demonstrate that
the majority of patients expressing
mutant p53 associated with Arg polymor-
phism have a poor response to
chemotherapy and a shorter survival.
This is the first large-scale study combin-
ing both basic research and clinical data
in order to more accurately evaluate the
role of the p53 signaling pathway in
human tumors.
These two studies published in
Cancer Cell will have important reper-
cussions for both basic research and
clinical practice. First of all, if the integrity
of the p73 signaling pathway is important
in the cellular and tumor response to
genotoxic agents, it is possible that p73
inactivation may be mediated by path-
ways other than p53 mutations. This
hypothesis is not easy to verify because,
unfortunately, it would be difficult to
develop a test evaluating the functional
status of p73 in tumors in view of the
mechanisms that inactivate p73. Only
large-scale studies combining observa-
tion of the molecular status of tumors
(expression profiles or mutational pro-
files) and functional studies would be
able to characterize these signaling
pathways. The second consequence of
these studies is that mutant p53 can
once again be considered to be onco-
genes with a well characterized gain of
function activity. Mutant p53 must be
considered to be a family of extremely
heterogeneous proteins, both structural-
ly and functionally, which will one day
need to be individually characterized
(Bullock and Fersht, 2001). The p53
gene mutation database currently con-
tains 3,200 variants for 15,000 listed
tumors (Soussi and Béroud, 2001). It
would be perfectly feasible to perform
systematic structural and functional
analysis linked with clinical data on the
50 variants most frequently identified in
human cancers (corresponding to 7,300
tumors, i.e., almost 50% of the data-
base), in order to establish the profile of
each mutation.
Finally, the most promising aspect of
the studies described here concerns the
therapeutic potential, as the use of si-
RNA specifically directed against mutant
p53 should restore chemosensitivity of
the tumor. It has already been demon-
strated that wild-type p53 and mutant
p53 can be distinguished by si-RNA,
suggesting that it would therefore be
possible to specifically target tumor cells
(Martinez et al., 2002). The mechanism
of action of p53 mutations, as demon-
strated by these studies, could well be its
Achilles’ heel. It is up to us to take advan-
tage of this opportunity!
Thierry Soussi*
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Deregulation of cell cycle control mecha-
nisms is an obligatory step in tumorigen-
esis. Myriad individual genetic events
lead to circumvention of checkpoints that
restrain the activity of cyclin/cyclin-
dependent kinase (cdk) complexes that
are responsible for managing cell cycle
transitions. Indeed, it is now widely
accepted that alteration of some compo-
nent of the retinoblastoma protein (pRb)
pathway, the core of which is depicted in
Figure 1, occurs in virtually all human
tumors. In some tumor cells, the RB gene
is a direct target of inactivating mutations,
but most often pRb is inactivated conse-
quent to inappropriate activation of the
cyclin D/cdk4(6) complex.This in turn can
be achieved through overexpression or
mutation of one of the subunits, or
through loss of the negative regulator
p16INK4a (Sherr and McCormick, 2002).
One of the most significant conse-
quences of pRb inactivation is activation
of cyclin E/cdk2 subunits, often as a
result of increased cyclin E expression.
Cyclin E/cdk2 complexes can themselves
participate in maintained inactivation of
pRb in tumor cells that express this pro-
tein, but also appear to have several
other critical roles in cell cycle progres-
sion (Bartek and Lukas, 2001). As shown
in Figure 1, cyclin E/cdk2 complexes are
thought to play critical roles in centro-
some duplication (Hinchcliffe and Sluder,
2002), replication origin firing (Krude et
al., 1997; Takisawa et al., 2000), and his-
tone protein expression (Ma et al. 2000;
Zhao et al., 2000). Consistent with such
crucial roles for cyclin E/cdk2 down-
stream of pRb, many tumor cells are
exquisitely sensitive to inactivation of
cyclin E/cdk2 whether or not they express
pRb. This conclusion has been drawn
from a multitude of experiments demon-
strating antiproliferative effects of overex-
pression of p27KIP1, a protein inhibitor of
cdk2, or of dominant-negative cdk2 sub-
units. Further, injection of antibodies
against cdk2 activators cyclin E and
cyclin A blocks proliferation, as does
treatment of many different cells with
cdk2 inhibitors (Tetsu and McCormick,
2003; Knockaert et al., 2002).
The view that pRb pathway inactiva-
tion has cyclin E/cdk2 activation as its
ultimate proliferative consequence is
supported by observations of mice engi-
neered to express cyclin E in place of
cyclin D1. Animals lacking cyclin D1 have
profound proliferative defects in a subset
of tissues, and fail to activate cdk2 in
those tissues.These phenotypes are sig-
nificantly suppressed in a knockin animal
that expresses cyclin E from the cyclin
D1 locus (Geng et al., 1999), suggesting
that loss of cyclin D-mediated inactiva-
tion of pRb is inconsequential if cyclin E
synthesis is no longer dependent on pRb
inactivation. Indeed, excess cyclin
E/cdk2 subunits can also overcome
ectopic expression of a nonphosphory-
latable, and thus constitutively active,
pRb (Bartek and Lukas, 2001). This
tumorigenic role of cyclin E/cdk2 may be
most clearly manifest in human breast
cancer cells, where reduced p27KIP1
expression or cyclin E overexpression
correlates well with aggressiveness of
the tumor (Catzavelos et al., 1997; Porter
et al., 1997; Keyomarsi et al., 2002). All
together, these studies suggest that
cyclin E/cdk2 regulation is targeted
directly and indirectly by multiple, collab-
orative mutational events in a wide vari-
ety of tumor cells and thus chemical
inhibition of cdk2 might provide an insur-
mountable obstacle to continued tumor
cell proliferation.
This view of cell cycle control in
cancer is now challenged by work from
Tetsu and McCormick reported in the
March issue of Cancer Cell. Using pri-
marily cell lines derived from colon can-
cers, Tetsu and McCormick have shown
that direct chemical inhibition of cdk4(6)
or indirect reduction of D cyclins and
cdk4 by MEK inhibitors blocks prolifera-
tion, but multiple modes of cdk2 inhibi-
tion are without effect. For example,
colon cancer cell lines proliferate with-
out regard to p27KIP1 or dncdk2 overex-
pression, but these same reagents do
cause arrest in other cell lines previous-
ly shown to respond to cdk2 inhibition.
Thus, colon cancer cells in general
appear to evade the effects of cdk2 inhi-
bition seen in other cancer cell types.
The authors suggest that one reason for
this is the ability of deregulated cdk4 to
fully inactivate pRb as a consequence
of eroded phosphorylation site specifici-
ty in tumor cells. Consistent with this,
Tetsu and McCormick show that one
form of dncdk4 can block proliferation of
Cdk2 dethroned as master of S phase entry
The prevailing view of cdk2 as a critical regulator of cell cycle progression and optimal therapeutic target in cancer cells is
now challenged by the observation that tumor cells deficient in cdk2 protein and kinase activity are not impaired in
proliferation.
